ENVB
NASDAQEnveric Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.76-0.06 (-3.56%)
02:00 PM04:30 PM
News · 26 weeks63-8%
2025-12-142026-06-07
Mix3590d
- SEC Filings15(43%)
- Other8(23%)
- Insider8(23%)
- Offering3(9%)
- Leadership1(3%)
Latest news
25 items- INSIDERChief Financial Officer Coveney Kevin Michael was granted 133,333 shares, increasing direct ownership by 281% to 180,746 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- INSIDERChief Executive Officer Tucker Joseph Edward was granted 201,124 shares, increasing direct ownership by 286% to 271,479 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- INSIDERDirector Pasqualone Frank was granted 18,518 shares, increasing direct ownership by 234% to 26,423 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- INSIDERDirector Webb Michael D was granted 18,518 shares, increasing direct ownership by 234% to 26,416 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- INSIDERDirector Schabacker Marcus was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- INSIDERDirector Kegler George A. was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- INSIDERDirector Dewitt Sheila was granted 18,518 shares, increasing direct ownership by 238% to 26,306 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- INSIDERChief Innovation Officer Facchini Peter J. was granted 25,000 shares, increasing direct ownership by 907% to 27,755 units (SEC Form 4)4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
- PREnveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003Studies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003. The initiated Good Laboratory Practice (GLP) studies will evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety requir
- SECSEC Form S-8 filed by Enveric Biosciences Inc.S-8 - Enveric Biosciences, Inc. (0000890821) (Filer)
- SECEnveric Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
- PREnveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003Analysis showed no photoreactive potential for EB-003, further derisking its continued development for the treatment of neuropsychiatric disorders including depression, anxiety and PTSD. Phototoxicity testing is a part of preclinical safety assessment evaluating whether a novel pharmaceutical compound could become harmful when exposed to UV light. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced promising results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive p
- SECSEC Form 10-Q filed by Enveric Biosciences Inc.10-Q - Enveric Biosciences, Inc. (0000890821) (Filer)
- SECEnveric Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
- PREnveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026Product Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects Corporate and Business Development Highlights: Strengthened intellectual property portfolio with new patent issuances and allowances across EVM301 and EVM401 series Announced the withdrawal by AbbVie, Inc. of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,27
- PREnveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric DisordersClaims to methods for treating a psychiatric disorder using novel pharmaceutical drug formulations encompass an EVM301 Series of drug candidates of carboxylated psilocybin derivatives, targeting various difficult-to-treat mental health disorders Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) issued to Enveric US Patent No. 12,605,361 (the '361 patent), titled, "Carboxylated Psilocybin Derivatives and Methods of Using," pertaining to the Company's EVM301 Series of m
- PREnveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical ModelPreviously reported results support continued development of EB-003 for PTSD and other neuropsychiatric conditions Recent U.S. Executive Order supporting psychedelic-inspired therapies highlights growing focus on PTSD and reinforces opportunity for neuroplastogens such as EB-003 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p <
- SECSEC Form D filed by Enveric Biosciences Inc.D - Enveric Biosciences, Inc. (0000890821) (Filer)
- SECEnveric Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
- SECSEC Form DEFA14A filed by Enveric Biosciences Inc.DEFA14A - Enveric Biosciences, Inc. (0000890821) (Filer)
- SECSEC Form EFFECT filed by Enveric Biosciences Inc.EFFECT - Enveric Biosciences, Inc. (0000890821) (Filer)
- SECSEC Form 424B3 filed by Enveric Biosciences Inc.424B3 - Enveric Biosciences, Inc. (0000890821) (Filer)
- PRLakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of DirectorsAppointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance
- SECSEC Form S-3 filed by Enveric Biosciences Inc.S-3 - Enveric Biosciences, Inc. (0000890821) (Filer)
- PREnveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics ForumEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will participate in a panel discussion at Needham's upcoming Virtual Psychedelics Forum. The panel, "Beyond TRD (Treatment-Resistant Depression): Non-Hallucinogens and New Indications," is scheduled for Monday, April 27, 1:00 PM - 2:00 PM ET. Event Details: Event: Needham's Virtual Psychedelics Forum Topic: Beyond TRD (Treatment-Resistant Depression): Non-Hallucinogens and New Indications Date & Time:
ENVB FAQ
6 questionsWhat does Enveric Biosciences Inc. do?
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.Where does ENVB stock trade?
Enveric Biosciences Inc. (ENVB) is listed on NASDAQ.What sector and industry is ENVB in?
Enveric Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ENVB?
Enveric Biosciences Inc. has had 3 recent analyst actions on file. The most recent action was from Aegis Capital: Hold with a $20.00 price target on 2022-03-08.What companies are similar to ENVB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ENVB side-by-side with any of them on Quantisnow.How can I track ENVB on Quantisnow?
Quantisnow aggregates Enveric Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENVB to receive live email and push alerts on every new disclosure.